GSK Formally Launches Tender Offer to Acquire Nuvalent
NUVL sits 74% above its 52-week low of $71.13 on light trading volume (0.2× avg).
Summary
GSK has formally launched its tender offer to acquire Nuvalent, initiating the process for shareholders to tender their shares. This follows the definitive merger agreement announced on June 9th, where GSK agreed to acquire Nuvalent for $10.6 billion, or $124.00 per share. The launch confirms the acquisition is progressing as planned and sets the stage for the deal's completion.
At the time of this announcement, NUVL was trading at $123.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $71.13 to $123.69. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.